Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells

被引:10
|
作者
Sasu, Barbra J. [1 ]
Opiteck, Gregory J. [1 ]
Gopalakrishnan, Suhasni [1 ]
Kaimal, Vivek [1 ]
Furmanak, Tom [1 ]
Huang, David [1 ]
Goswami, Angshumala [1 ]
He, Ying [1 ]
Chen, Jiamin [1 ]
Nguyen, Anh [1 ]
Balakumaran, Arun [1 ]
Shah, Nirav N. [2 ]
Hamadani, Mehdi [2 ]
Bone, Kathleen M. [3 ]
Prashad, Sacha [1 ]
Bowen, Michael A. [1 ]
Pertel, Thomas [1 ]
Embree, Heather D. [1 ]
Gidwani, Shalini G. [1 ]
Chang, David [1 ]
Moore, Alison [1 ]
Leonard, Mark [1 ]
Amado, Rafael G. [1 ]
机构
[1] Allogene Therapeut, San Francisco, CA 94080 USA
[2] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
关键词
INVERSION; IMMUNOGLOBULIN; RECOMBINATION; IMMUNOTHERAPY; LYMPHOCYTES; INTEGRATION; ALIGNMENT; LYMPHOMA; THERAPY; SITES;
D O I
10.1016/j.ymthe.2022.12.004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A chromosome 14 inversion was found in a patient who devel-oped bone marrow aplasia following treatment with allogeneic chimeric antigen receptor (CAR) Tcells containing gene edits made with transcription activator-like effector nucleases (TALEN). TALEN editing sites were not involved at either breakpoint. Recombination signal sequences (RSSs) were found suggesting recombination-activating gene (RAG) -medi-ated activity. The inversion represented a dominant clone de-tected in the context of decreasing absolute CAR Tcell and overall lymphocyte counts. The inversion was not associated with clinical consequences and wasnot detected in the drug product administered to this patient or in any drug product used in this or other trials using the same manufacturing pro-cesses. Neither was the inversion detected in this patient at earlier time points or in any other patient enrolled in this or other trials treated with this or other product lots. This case il-lustrates that spontaneous, possibly RAG-mediated, recombi-nation events unrelated to gene editing can occur in adoptive cell therapy studies, emphasizes the need for ruling out off -target gene editing sites, and illustrates that other processes, such as spontaneous V(D)J recombination, can lead to chromo-somal alterations in infused cells independent of gene editing.
引用
收藏
页码:676 / 685
页数:10
相关论文
共 50 条
  • [21] Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning
    Stepanova, Valeria M.
    Volkov, Dmitry V.
    Osipova, Daria S.
    Wang, Wenjian
    Hou, Yingqin
    Pershin, Dmitry E.
    Fadeeva, Mariia S.
    Malakhova, Ekaterina A.
    Kulakovskaya, Elena A.
    Lui, Cuicui
    Zhao, Mingfeng
    Zhang, Hongkai
    Xie, Jia
    Zhang, Ding
    Mamedov, Ilgar Z.
    Chernov, Alexandr S.
    Telegin, Georgij B.
    Rubtsov, Yuri P.
    Gabibov, Alexander G.
    Wu, Peng
    Maschan, Michael A.
    Stepanov, Alexey, V
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (03):
  • [22] CRISPR/CAS9 GENE-EDITED, ALLOGENEIC ANTI-CD83 CAR-T CELLS DEMONSTRATE POTENT ACTIVITY IN GVHD AND AML TUMOR MODELS
    Oumzil, Ismael
    Guerrero, Valerie
    Keerthipati, Pooja Smruthi
    Colangelo, Jaqlyn
    Lawler, Brendan
    Singson, Victoria
    Khedkar, Aditya
    Singh, Shweta
    Terrett, Jonathan
    Hostetter, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A386 - A386
  • [23] NOVEL GENE-EDITED CAR-T CELL THERAPY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA
    Balakrishnan, Ilango
    Leach, Lillie
    Lakshmanachetty, Senthilnath
    Pierce, Angela
    Madhavan, Krishna
    Chatwin, Hannah
    Fosmire, Susan
    Meadows, Christina
    Green, Adam
    Fry, Terry
    Vibhakar, Rajeev
    Kohler, Eric M.
    Venkataraman, Sujatha
    NEURO-ONCOLOGY, 2022, 24 : 86 - 86
  • [24] Gene-edited vero cells as rotavirus vaccine substrates
    Orr-Burks, Nichole
    Murray, Jackelyn
    Wu, Weilin
    Kirkwood, Carl D.
    Todd, Kyle, V
    Jones, Les
    Bakre, Abhijeet
    Wang, Houping
    Jiang, Baoming
    Tripp, Ralph A.
    VACCINE: X, 2019, 3
  • [25] DEVELOPMENT OF A CLINICAL-SCALE GMP-COMPLIANT GENE-EDITED CAR T CELL MANUFACTURING PROCESS
    Park, J.
    Zheng, F.
    Kim-Hoehamer, Y.
    Shang, N.
    Lin, J.
    Krenciute, G.
    Youngblood, B.
    Riberdy, J. M.
    Lazzarotto, C.
    Ferrara, F.
    Diao, S.
    Wilbourne, J.
    Lockey, T.
    Whittaker, S.
    Tsai, S.
    Throm, R.
    Pruett-Miller, S. M.
    Valentine, M.
    Meagher, M.
    Talleur, A.
    Gottschalk, S.
    Zhou, S.
    CYTOTHERAPY, 2023, 25 (06) : S209 - S209
  • [26] Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env plus cells in vivo
    Pan, Hanyu
    Yang, Xinyi
    Wang, Jing
    Liang, Huitong
    Jiang, Zhengtao
    Zhao, Lin
    Wang, Yanan
    Liang, Zhiming
    Shen, Xiaoting
    Lin, Qinru
    Liang, Yue
    Yang, Jinglong
    Lu, Panpan
    Zhu, Yuqi
    Li, Min
    Wang, Pengfei
    Xu, Jianqing
    Lu, Hongzhou
    Zhu, Huanzhang
    VIROLOGICA SINICA, 2023, 38 (02) : 285 - 295
  • [27] BAR-Seq clonal tracking of gene-edited cells
    Ferrari, Samuele
    Beretta, Stefano
    Jacob, Aurelien
    Cittaro, Davide
    Albano, Luisa
    Merelli, Ivan
    Naldini, Luigi
    Genovese, Pietro
    NATURE PROTOCOLS, 2021, 16 (06) : 2991 - 3025
  • [28] BAR-Seq clonal tracking of gene-edited cells
    Samuele Ferrari
    Stefano Beretta
    Aurelien Jacob
    Davide Cittaro
    Luisa Albano
    Ivan Merelli
    Luigi Naldini
    Pietro Genovese
    Nature Protocols, 2021, 16 : 2991 - 3025
  • [29] Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells
    Guo, Rongqun
    Li, Wei
    Li, Yadan
    Li, Yingmei
    Jiang, Zhongxing
    Song, Yongping
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [30] Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells
    Rongqun Guo
    Wei Li
    Yadan Li
    Yingmei Li
    Zhongxing Jiang
    Yongping Song
    Experimental Hematology & Oncology, 11